AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 100 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg b.i.d. plus reduced tacrolimus (rTAC; 2‐5 ng/mL)
Number of subjects: 298
Study 23668931 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated mycophenolic acid (MPA) plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg and 300 mg
Number of subjects: 298
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin groups
Number of subjects: 298
Study 23668931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin (all doses)
Number of subjects: 298
Study 20386125 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 43% 1RM
Number of subjects: 20
Study 20386125 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 23% 1RM
Number of subjects: 20
Study 20386125 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study 18436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day (prava40)
Number of subjects: 120
Study 18436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (atorva10)
Number of subjects: 120
Study 18436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (atorva80)
Number of subjects: 120
Study 18436117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16950753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-caloric diet for obese women
Number of subjects: 36
Study 12759881 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TGZ)
Number of subjects: 0
Study 12759881 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 0
Study 11043625 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal creatine phosphokinase (CPK) levels >70 mIU/dL
Number of subjects: 42
Study 11043625 — intervention group
Group type: EXPERIMENTAL
Intervention: CPK >70 mIU/dL
Number of subjects: 42
Study 9168185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (with booster)
Number of subjects: 828
Study 9168185 — intervention group
Group type: COMPARATOR
Intervention: Telephone confirmation
Number of subjects: 828
Study 9168185 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 828
Study 9168185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (prior to initial visit)
Number of subjects: 828
Study 9168185 — intervention group
Group type: COMPARATOR
Intervention: Telephone confirmation (for 6-month follow-up)
Number of subjects: 828
Study 9168185 — intervention group
Group type: COMPARATOR
Intervention: Standard care (for 6-month follow-up)
Number of subjects: 828
Study 8477190 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha alone (arm A)
Number of subjects: 131
Study 8477190 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha and IFN gamma (arm B)
Number of subjects: 131
Study 3797397 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide screening and education program
Number of subjects: 0
Study 3797397 — intervention group
Group type: COMPARATOR
Intervention: Excluded from the screening and education program
Number of subjects: 0
Study 30048834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week inpatient pulmonary rehabilitation
Number of subjects: 590
Study 27423981 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (routine coronary angiogram, n=52)
Number of subjects: 106
Study 27423981 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (coronary angiogram only if recurrent ischemia or heart failure, n=54)
Number of subjects: 106
Study 27423981 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 106
Study 24507016 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine) 1-4 mg twice daily (BID)
Number of subjects: 614
Study 24507016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 24507016 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine) 1-4 mg BID
Number of subjects: 614
Study 22753445 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 23
Study 22753445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20400408 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine
Number of subjects: 1203
Study 20400408 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study 18722869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 883
Study 18722869 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 883
Study 18722869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 883
Study 18722869 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 883
Study 16908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents
Number of subjects: 200
Study 16908768 — intervention group
Group type: COMPARATOR
Intervention: Bare metal BxVelocity stents
Number of subjects: 200
Study 14626182 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Zaizhang decoction (ZZD)
Number of subjects: 0
Study 14626182 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 14626182 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 0
Study 10857523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise using arm and bicycle ergometers performed twice a day, 5 times a week, for 14 days, at 60% of maximal heart rate.
Number of subjects: 35
Study 10857523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 35
Study 9190630 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 2646
Study 8254142 — intervention group
Group type: EXPERIMENTAL
Intervention: Light treatment administered at the first signs of winter depression
Number of subjects: 27
Study 8254142 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 27
Study 3799250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal operation of the pituitary adenoma
Number of subjects: 50
Study 3799250 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 31276886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate (1 mg/L)
Number of subjects: 0
Study 31276886 — intervention group
Group type: EXPERIMENTAL
Intervention: Roundup (1 mg/L of glyphosate a.e.)
Number of subjects: 0
Study 31276886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate or Roundup
Number of subjects: 0
Study 31276886 — intervention group
Group type: EXPERIMENTAL
Intervention: Roundup (1 mg/L of glyphosate a.e.) with androgenic gland
Number of subjects: 0
Study 27738796 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 32-mg infusion over 24 hours
Number of subjects: 62
Study 27738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine wafer 10 mg once daily plus ondansetron 8 mg IV three times a day
Number of subjects: 62
Study 27738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV
Number of subjects: 62
Study 25894123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus + cyclosporine + prednisolone for 3 months followed by sirolimus + prednisolone + mycophenolate mofetil with steroid minimization
Number of subjects: 113
Study 25894123 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine + mycophenolate mofetil + prednisolone
Number of subjects: 113
Study 23136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine (100 mg/day for 12 weeks)
Number of subjects: 36
Study 23136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine (100 mg/day for 8 weeks)
Number of subjects: 36
Study 21513180 — intervention group
Group type: EXPERIMENTAL
Intervention: High salience and high relevance changes
Number of subjects: 0
Study 21513180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salience changes
Number of subjects: 0
Study 21513180 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in the left visual hemifield
Number of subjects: 0
Study 21513180 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (men vs. women)
Number of subjects: 0
Study 19566934 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC)
Number of subjects: 6112
Study 19566934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112
Study 17006787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month training program
Number of subjects: 19
Study 17006787 — intervention group
Group type: COMPARATOR
Intervention: No training group
Number of subjects: 19
Study 14683522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean‐inspired diet rich in omega‐3 fatty acids and sterol esters, low in saturated fat, for 4 weeks
Number of subjects: 22
Study 14683522 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Swedish diet for 4 weeks
Number of subjects: 22
Study 11331113 — intervention group
Group type: EXPERIMENTAL
Intervention: First aid and home safety training
Number of subjects: 660
Study 11331113 — intervention group
Group type: COMPARATOR
Intervention: Tobacco and alcohol prevention
Number of subjects: 660
Study 9422899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.0 mg kg-1 i.v.
Number of subjects: 107
Study 9422899 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 0.5 mg kg-1 i.v.
Number of subjects: 107
Study 8290458 — intervention group
Group type: EXPERIMENTAL
Intervention: OAD cream
Number of subjects: 56
Study 3014110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 18
Study 3014110 — intervention group
Group type: COMPARATOR
Intervention: Fed regimen (following a standardized breakfast)
Number of subjects: 18
Study 30403938 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide and dexamethasone
Number of subjects: 117
Study 30403938 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone alone (control group)
Number of subjects: 117
Study 26788865 — intervention group
Group type: EXPERIMENTAL
Intervention: APTW imaging for true progression (n=20)
Number of subjects: 32
Study 26788865 — intervention group
Group type: COMPARATOR
Intervention: APTW imaging for pseudoprogression (n=12)
Number of subjects: 32
Study 26788865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff APTWmean intensity
Number of subjects: 32
Study 26788865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff APTWmax intensity
Number of subjects: 32
Study 24807604 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-releasing suppository
Number of subjects: 122
Study 24807604 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 122
Study 22233558 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+LLLT (10 sessions, 830 nm, 100 mW, 3 J per point, 3 J/cm²)
Number of subjects: 16
Study 22233558 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 16
Study 20444751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate (MTX) and ciclosporin (CSA), n=80
Number of subjects: 139
Study 20444751 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy with methotrexate (MTX), n=80
Number of subjects: 139
Study 20444751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (MTX + CSA and MTX)
Number of subjects: 139
Study 20444751 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-bone marrow oedema, TSS, and anti-CCP
Number of subjects: 139
Study 18635500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine and 100 mg tramadol (group BT)
Number of subjects: 90
Study 18635500 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tramadol (group T)
Number of subjects: 90
Study 18635500 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (group B)
Number of subjects: 90
Study 15837944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise training
Number of subjects: 39
Study 15837944 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 39
Study 15837944 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean children)
Number of subjects: 39
Study 12392384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg administered once daily
Number of subjects: 809
Study 12392384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 10516539 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine bronchial challenge
Number of subjects: 40
Study 10516539 — intervention group
Group type: COMPARATOR
Intervention: Methacholine bronchial challenge
Number of subjects: 40
Study 8611112 — intervention group
Group type: EXPERIMENTAL
Intervention: Active loperamide suppositories (20 mg b.d. x 1 week)
Number of subjects: 10
Study 8611112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2167791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of atrial natriuretic factor at doses of 0.5, 2 and 10 pmol min‐1 kg‐1
Number of subjects: 8
Study 2167791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of atrial natriuretic factor at a pharmacological dose of 50 pmol min‐1 kg‐1
Number of subjects: 8
Study 6944146 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral oncolysate (formalin-treated fowl plaque virus-infected allogenous leukemia cells) in addition to maintenance chemotherapy
Number of subjects: 107
Study 6944146 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 107
Study 30889042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with bevacizumab
Number of subjects: 294
Study 30889042 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine without bevacizumab
Number of subjects: 294
Study 29537374 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNIR stent
Number of subjects: 302
Study 29537374 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity stent
Number of subjects: 302
Study 26092029 — intervention group
Group type: COMPARATOR
Intervention: Mesh fixation (control group)
Number of subjects: 60
Study 26092029 — intervention group
Group type: EXPERIMENTAL
Intervention: No mesh fixation (NO FIX group)
Number of subjects: 60
Study 24915778 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib plus gemcitabine
Number of subjects: 160
Study 24915778 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 160
Study 21593672 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 116
Study 21593672 — intervention group
Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 116
Study 21593672 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel (novices)
Number of subjects: 116
Study 21593672 — intervention group
Group type: COMPARATOR
Intervention: cLMA (novices)
Number of subjects: 116
Study 21593672 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel (experienced)
Number of subjects: 116
Study 21593672 — intervention group
Group type: COMPARATOR
Intervention: cLMA (experienced)
Number of subjects: 116
Study 19303238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral access (USIV)
Number of subjects: 60
Study 19303238 — intervention group
Group type: COMPARATOR
Intervention: External jugular vein access (EJ)
Number of subjects: 60
Study 17683540 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs (cyclooxygenase-2 selective inhibitors)
Number of subjects: 49006
Study 17683540 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 49006
Study 17683540 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 49006
Study 17683540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 49006
Study 17683540 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 49006
Study 17683540 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs
Number of subjects: 49006
Study 15249439 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 24
Study 15249439 — intervention group
Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 24
Study 11832872 — intervention group
Group type: EXPERIMENTAL
Intervention: High CHO/low fat diet (HC/LF)
Number of subjects: 18
Study 11832872 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CHO and fat diet (MC/MF)
Number of subjects: 18
Study 11832872 — intervention group
Group type: COMPARATOR
Intervention: Active control group (aerobically trained)
Number of subjects: 18
Study 11832872 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 18
Study 10410789 — intervention group
Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine 0.1% ophthalmic solution
Number of subjects: 30
Study 10410789 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 7538556 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral-blood progenitor cells (PBPC)
Number of subjects: 47
Study 7538556 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 47
Study 2405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin IV
Number of subjects: 207
Study 2405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin lavage
Number of subjects: 207
Study 2405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole IV
Number of subjects: 207
Study 2405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole lavage
Number of subjects: 207
Study 2405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometritis (developed)
Number of subjects: 207
Study 2405316 — intervention group
Group type: COMPARATOR
Intervention: Endometritis (not developed)
Number of subjects: 207
Study 548976 — intervention group
Group type: EXPERIMENTAL
Intervention: Active haemodialysis (AD)
Number of subjects: 12
Study 548976 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis (SD)
Number of subjects: 12
Study 31860383 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated formulation (RF) of VGX-3100
Number of subjects: 235
Study 31860383 — intervention group
Group type: COMPARATOR
Intervention: Frozen formulation (FF) of VGX-3100
Number of subjects: 235
Study 30967124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 0
Study 30967124 — intervention group
Group type: COMPARATOR
Intervention: Landmark method
Number of subjects: 0
Study 28278558 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Index (VAI)
Number of subjects: 5312
Study 28278558 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 5312
Study 26134388 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed mucilage (10 g)
Number of subjects: 58
Study 26134388 — intervention group
Group type: COMPARATOR
Intervention: L. paracasei F19 (9.4 × 10^10 colony-forming units)
Number of subjects: 58
Study 26134388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane-covered antrostomy defects
Number of subjects: 109
Study 24164570 — intervention group
Group type: COMPARATOR
Intervention: Uncovered antrostomy defects
Number of subjects: 109
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane coverage (split-mouth study)
Number of subjects: 109
Study 24164570 — intervention group
Group type: COMPARATOR
Intervention: Uncovered (split-mouth study)
Number of subjects: 109
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed implant placement
Number of subjects: 109
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick Schneider's membrane (≥2 mm)
Number of subjects: 109
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 109
Study 24164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking
Number of subjects: 109
Study 21324384 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Number of subjects: 88
Study 21324384 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 88
Study 21324384 — intervention group
Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 88
Study 20031746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus-aspiration PCI
Number of subjects: 111
Study 20031746 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 111
Study 20031746 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 111
Study 17890965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation at the arm (maximal pressures of 180 and 240 mmHg)
Number of subjects: 68
Study 17890965 — intervention group
Group type: COMPARATOR
Intervention: Cuff inflation at the wrist (maximal pressures of 180 and 240 mmHg)
Number of subjects: 68
Study 14624322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 33
Study 15039810 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 15039810 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 10626860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 65
Study 10626860 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 65
Study 10626860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Number of subjects: 10